Drugs / MenACWY Ad+
last change Oct 2006 re-read 2 minutes ago

MenACWY Ad+

also known as MenACWY-CRM

Vaccine

Developed for
meningococcemia
Investigated by
Novartis · Novartis Vaccines

Trials 1 · a red edge is where a trial was stopped

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00262002 Sep 2004 → Jul 2005 meningococcemia Novartis Vaccines Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MenACWY Ad+ ClinicalTrials.gov intervention name — accepted as the source's own label NCT00262002
Known as MenACWY-CRM “MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)” NCT00262002
Modality Vaccine “MenACWY-CRM conjugate vaccine formulated with adjuvant” NCT00262002
Route Intramuscular “was injected IM in the anterolateral area of the right thigh” NCT00262002